Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLINASDAQ:EYPTNASDAQ:OMIC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLIBerkeley Lights$0.77$1.14▼$7.79$72.04M1.36845,024 shsN/AEYPTEyePoint Pharmaceuticals$20.67-0.7%$25.61$2.87▼$30.99$1.04B1.66995,155 shs1.14 million shsOMICSingular Genomics Systems$0.51$0.53$0.31▼$1.32$38.21M1.498,447 shs56,504 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLIBerkeley Lights0.00%0.00%0.00%0.00%-4.03%EYPTEyePoint Pharmaceuticals-0.67%-11.74%-27.90%-10.56%+507.94%OMICSingular Genomics Systems-0.50%+4.36%-12.55%+11.76%-55.29%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLIBerkeley LightsN/AN/AN/AN/AN/AN/AN/AN/AEYPTEyePoint Pharmaceuticals2.3704 of 5 stars3.51.00.00.03.24.20.0OMICSingular Genomics Systems1.8746 of 5 stars3.02.00.00.02.03.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLIBerkeley LightsN/AN/AN/AN/AEYPTEyePoint Pharmaceuticals3.00Buy$33.8663.80% UpsideOMICSingular Genomics Systems2.00Hold$0.6831.27% UpsideCurrent Analyst RatingsLatest EYPT, BLI, and OMIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2024OMICSingular Genomics SystemsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$0.40 ➝ $0.502/16/2024EYPTEyePoint PharmaceuticalsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/16/2024EYPTEyePoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $39.001/22/2024EYPTEyePoint PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$35.001/22/2024OMICSingular Genomics SystemsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$0.95 ➝ $0.851/16/2024EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $33.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLIBerkeley Lights$78.60M0.00N/AN/A$2.07 per share0.00EYPTEyePoint Pharmaceuticals$46.02M22.38N/AN/A$5.66 per share3.65OMICSingular Genomics Systems$2.91M13.06N/AN/A$2.44 per share0.21Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLIBerkeley Lights-$98.04M-$1.43N/AN/AN/A-124.74%-57.56%-39.40%N/AEYPTEyePoint Pharmaceuticals-$70.79M-$1.83N/AN/AN/A-153.84%-61.48%-33.49%5/1/2024 (Estimated)OMICSingular Genomics Systems-$94.82M-$1.31N/A∞N/A-3,257.30%-45.33%-33.29%5/14/2024 (Estimated)Latest EYPT, BLI, and OMIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023OMICSingular Genomics SystemsN/A-$0.34-$0.34-$0.32N/A$1.08 million 3/7/202412/31/2023EYPTEyePoint Pharmaceuticals-$0.60-$0.33+$0.27-$0.33$8.71 million$14.03 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLIBerkeley LightsN/AN/AN/AN/AN/AEYPTEyePoint PharmaceuticalsN/AN/AN/AN/AN/AOMICSingular Genomics SystemsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLIBerkeley Lights0.103.893.48EYPTEyePoint PharmaceuticalsN/A5.455.39OMICSingular Genomics Systems0.0510.519.77OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLIBerkeley Lights68.43%EYPTEyePoint Pharmaceuticals99.41%OMICSingular Genomics Systems65.80%Insider OwnershipCompanyInsider OwnershipBLIBerkeley Lights17.60%EYPTEyePoint Pharmaceuticals13.05%OMICSingular Genomics Systems21.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLIBerkeley Lights29372.17 million59.47 millionNot OptionableEYPTEyePoint Pharmaceuticals12149.83 million43.33 millionOptionableOMICSingular Genomics Systems28473.93 million57.74 millionOptionableEYPT, BLI, and OMIC HeadlinesSourceHeadlineNucleus Genomics Logo (IMAGE)eurekalert.org - March 26 at 5:28 AMSingular Genomics Systems (NASDAQ:OMIC) Price Target Raised to $0.50americanbankingnews.com - March 22 at 2:56 AMSingular Genomics Systems (NASDAQ:OMIC) PT Raised to $0.50americanbankingnews.com - March 22 at 2:56 AMSingular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 20 at 3:08 PMSingular Genomics Systems, Inc. (NASDAQ:OMIC) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 20 at 3:08 PMSingular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 19 at 11:42 AMSingular Genomics Sys: Q4 Earnings Insightsbenzinga.com - March 18 at 8:12 PMSingular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 18 at 4:05 PMSingular Genomics Systems earnings: here's what to expectmarkets.businessinsider.com - March 17 at 2:09 PMPreview: Singular Genomics Sys's Earningsbenzinga.com - March 15 at 2:20 PMSingle-cell RNA-seq reveals transcriptomic modulation of Alzheimer's disease by activated protein Cmsn.com - March 15 at 1:39 AMNovel gene editing tool analyzes sperm health in animalsmsn.com - March 11 at 8:58 AMSingular Genomics Systems files patent for image analysis method for quantifying features in patternspharmaceutical-technology.com - March 11 at 8:58 AMAnalysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), ZimVie Inc (ZIMV) and Veeva Systems (VEEV)markets.businessinsider.com - March 5 at 7:07 AMSingular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024globenewswire.com - March 4 at 4:05 PMSingular Genomics Systems Inc.wsj.com - February 24 at 1:56 PMSingular Genomics Systems, Inc.: Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysisfinanznachrichten.de - February 5 at 2:11 PMJPM: Illumina’s New CEO Spells Out 2024 Priorities, Presents Preliminary Q4, 2023 Resultsgenengnews.com - January 10 at 12:42 PMSingular Genomics reports instrument shipments, preliminary Q4 revenuemsn.com - January 8 at 8:02 AMSingular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenuefinance.yahoo.com - January 7 at 7:48 PMAnalysts Offer Insights on Healthcare Companies: Illumina (ILMN), Pfizer (PFE) and Neurogene (NGNE)markets.businessinsider.com - January 4 at 6:25 PMSingular Genomics Systems Founder Acquires 4.6% More Stockfinance.yahoo.com - November 21 at 7:09 AMHold Rating on Singular Genomics Systems (OMIC) Amid Q3 Underperformance and Strategy Shiftmarkets.businessinsider.com - November 16 at 11:05 PMInsider Selling: Kamdar Kim P., Singular Genomics Systems Inc [OMIC] Director divested 200,000 sharesknoxdaily.com - November 16 at 8:02 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksSea Limited: The One-Stop Digital Consumer Platform of AsiaMarch 13, 2024 6:10 AMView Sea Limited: The One-Stop Digital Consumer Platform of AsiaDoes Reddit's Successful Public Debut Mean Tech IPOs are Back?March 22, 2024 6:15 AMView Does Reddit's Successful Public Debut Mean Tech IPOs are Back?All Headlines Company DescriptionsBerkeley LightsNASDAQ:BLIBerkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.EyePoint PharmaceuticalsNASDAQ:EYPTEyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Singular Genomics SystemsNASDAQ:OMICSingular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.